The Rise Of Complex OSD generics: Understanding Development Challenges

The oral solid dose (OSD) contract manufacturing market is experiencing significant growth, with its value projected to increase from $37.82 billion in 2024 to $57.02 billion by 2032. While traditional OSD generics continue to play a vital role in the market, there is a noticeable shift toward more complex generic OSD formulations. These complex formulations often involve difficult-to-manufacture technologies, such as extended-release or modified-release profiles, which present unique challenges in both development and production.

As pharmaceutical companies navigate these advanced manufacturing processes, the demand for specialized techniques, expertise, and capabilities is growing. Additionally, the evolving regulatory landscape presents further obstacles that require careful navigation. To streamline their path to market, many companies are increasingly turning to outsourcing development and manufacturing partners who can provide the necessary support and expertise.

However, the journey is not without its challenges. How can the right partner help pharmaceutical companies overcome these hurdles and confidently bring their products to market? Understanding the potential pitfalls and partnering with the right experts can make all the difference in overcoming the complexities of complex generic OSD development.